Quest Diagnostics (NYSE:DGX) Stock

Quest Diagnostics

Quest Diagnostics Inc is a leading independent provider of diagnostic testing, information, and services in the us. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics Inc

Digi Power X Inc. - Common Subordinate Voting Shares

Digi Power X Inc

Piper Sandler analyst David Westenberg maintains Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) with a Neutral and raises the price target from $180 to $200.

News

Price Target

Analyst Ratings

Piper Sandler Maintains Neutral on Quest Diagnostics, Raises Price Target to $200

Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) has outperformed the market over the past 5 years by 290.7% on an annualized basis producing an average annual return of 304.55%. Currently, Quest Diagnostics has a market capitalization of $19.69 billion. 
Buying $1000 In DGX: If an investor had bought $1000 of DGX stock 5 years ago, it would be worth $1,149,477.12 today based on a price of $175.87 for DGX at the time of writing.
<h3>Quest Diagnostics's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745536510_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning Quest Diagnostics Stock In The Last 5 Years

Quest Diagnostics Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) posted better-than-expected first-quarter <a href="https://www.benzinga.com/quote/DGX/earnings">earnings on Tuesday</a>.
Quest Diagnostics reported quarterly earnings of $2.21 per share which beat the analyst consensus estimate of $2.15 per share. The company reported quarterly sales of $2.65 billion which beat the analyst consensus estimate of $2.63 billion.
"In the first quarter, we delivered strong revenue growth of approximately 12%, including nearly 2.5% in organic growth, as demand rebounded in March following weather impacts early in the quarter. Our growth was due to contributions from acquisitions and large enterprise accounts, demand for our advanced diagnostics portfolio, and expanded health plan access," said Jim Davis, chairman, CEO and president. "We are reaffirming our revenue and adjusted EPS guidance for the full year 2025."
Quest Diagnostics reaffirmed 2025 guidance for revenue of $10.70 billion—$10.85 billion versus the consensus of $10.78 billion and adjusted EPS of $9.55-$9.80 compared to the consensus of $9.68.
Quest Diagnostics shares fell 0.1% to trade at $172.71 on Wednesday.
These analysts made changes to their price targets on Quest Diagnostics following earnings announcement.
<ul>
<li>Baird analyst Eric Coldwell maintained Quest Diagnostics with an Outperform rating and raised the price target from $191 to $194.</li>
<li>Evercore ISI Group analyst Elizabeth Anderson maintained the stock with an In-Line rating and raised the price target from $175 to $180.</li>
<li>Barclays analyst Stephanie Davis maintained Quest Diagnostics with an Equal-Weight rating and increased the price target from $175 to $185.</li>
<li>Truist Securities analyst David Macdonald maintained the stock with a Hold rating and raised the price target from $182 to $190.</li>
</ul>
Considering buying DGX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="591" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23131602/image-139-1024x591.png" alt="" class="wp-image-884833" style="width:582px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23131602/image-139-1024x591.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23131602/image-139-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23131602/image-139-768x443.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23131602/image-139.png 1092w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44950904/tesla-to-303-here-are-10-top-analyst-forecasts-for-wednesday">Tesla To $303? Here Are 10 Top Analyst Forecasts For Wednesday</a> </li>
</ul>
Photo via Shutterstock

Earnings

Markets

These Analysts Boost Their Forecasts On Quest Diagnostics After Better-Than-Expected Q1 Earnings

Truist Securities analyst David Macdonald maintains Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) with a Hold and raises the price target from $182 to $190.

Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $190

Barclays analyst Stephanie Davis maintains Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) with a Equal-Weight and raises the price target from $175 to $185.

Barclays Maintains Equal-Weight on Quest Diagnostics, Raises Price Target to $185

During the last three months, 12 analysts shared their evaluations of Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $183.25, with a high estimate of $195.00 and a low estimate of $170.00. Observing a 3.91% increase, the current average has risen from the previous average price target of $176.36. 
<img src="https://www.benzinga.com/files/images/story/2025/1745413266_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Quest Diagnostics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Elizabeth Anderson &#x7C;Evercore ISI Group &#x7C;Raises &#x7C;In-Line &#x7C; $180.00&#x7C;$175.00 &#x7C; 
&#x7C;Eric Coldwell &#x7C;Baird &#x7C;Raises &#x7C;Outperform &#x7C; $194.00&#x7C;$191.00 &#x7C; 
&#x7C;Ann Hynes &#x7C;Mizuho &#x7C;Raises &#x7C;Outperform &#x7C; $189.00&#x7C;$178.00 &#x7C; 
&#x7C;Jamie Clark &#x7C;Redburn Atlantic &#x7C;Announces &#x7C;Buy &#x7C; $195.00&#x7C;- &#x7C; 
&#x7C;Eric Coldwell &#x7C;Baird &#x7C;Raises &#x7C;Outperform &#x7C; $191.00&#x7C;$190.00 &#x7C; 
&#x7C;Patrick Donnelly &#x7C;Citigroup &#x7C;Maintains &#x7C;Neutral &#x7C; $185.00&#x7C;$185.00 &#x7C; 
&#x7C;Lisa Gill &#x7C;JP Morgan &#x7C;Raises &#x7C;Neutral &#x7C; $180.00&#x7C;$173.00 &#x7C; 
&#x7C;Ann Hynes &#x7C;Mizuho &#x7C;Raises &#x7C;Outperform &#x7C; $178.00&#x7C;$177.00 &#x7C; 
&#x7C;Kevin Caliendo &#x7C;UBS &#x7C;Raises &#x7C;Neutral &#x7C; $170.00&#x7C;$166.00 &#x7C; 
&#x7C;David Westenberg &#x7C;Piper Sandler &#x7C;Raises &#x7C;Neutral &#x7C; $180.00&#x7C;$165.00 &#x7C; 
&#x7C;David Macdonald &#x7C;Truist Securities &#x7C;Raises &#x7C;Hold &#x7C; $182.00&#x7C;$172.00 &#x7C; 
&#x7C;Stephanie Davis &#x7C;Barclays &#x7C;Raises &#x7C;Equal-Weight &#x7C; $175.00&#x7C;$168.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Quest Diagnostics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Quest Diagnostics compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Quest Diagnostics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Capture valuable insights into Quest Diagnostics's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DGX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Quest Diagnostics analyst ratings.</a>
<h2>Get to Know Quest Diagnostics Better</h2>
Quest Diagnostics Inc is a leading independent provider of diagnostic testing, information, and services in the us. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
<h3>Financial Milestones: Quest Diagnostics's Journey</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Positive Revenue Trend: Examining Quest Diagnostics's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 14.55% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Quest Diagnostics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 8.39%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Quest Diagnostics's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 3.24%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Quest Diagnostics's ROA excels beyond industry benchmarks, reaching 1.36%. This signifies efficient management of assets and strong financial health.
Debt Management: Quest Diagnostics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.05.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Quest Diagnostics Through 12 Analysts

Evercore ISI Group analyst Elizabeth Anderson maintains Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) with a In-Line and raises the price target from $175 to $180.

Evercore ISI Group Maintains In-Line on Quest Diagnostics, Raises Price Target to $180

Baird analyst Eric Coldwell maintains Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) with a Outperform and raises the price target from $191 to $194.

Baird Maintains Outperform on Quest Diagnostics, Raises Price Target to $194

Quest Diagnostics Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) reported on Tuesday that first-quarter 2025 sales of $2.65 billion, up 12.1% year over year, beat the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $2.63 billion</a>.
The diagnostic test provider reported quarterly adjusted earnings of $2.21 per share, up 8.3%, <a href="https://www.benzinga.com/pressreleases/25/04/n44917998/quest-diagnostics-reports-first-quarter-2025-financial-results-reaffirms-revenue-and-adjusted-dilu" target="_blank" rel="noreferrer noopener">beating the consensus of $2.15</a>.
&#8220;In the first quarter, we delivered strong revenue growth of approximately 12%, including nearly 2.5% in organic growth, as demand rebounded in March following weather impacts early in the quarter. Our growth was due to contributions from acquisitions and large enterprise accounts, demand for our advanced diagnostics portfolio, and expanded health plan access,&#8221; said Jim Davis, chairman, CEO and president. &#8220;We are reaffirming our revenue and adjusted EPS guidance for the full year 2025.&#8221; 
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/04/44921124/ge-aerospace-expands-q1-operating-margins-ceo-talks-cost-control-to-mitigate-tariff-impact" rel="noreferrer noopener">GE Aerospace Expands Q1 Operating Margins, CEO Talks Cost Control To Mitigate Tariff Impact</a>
Revenue per requisition increased by 0.3%, requisition volume increased 12.4% and organic requisition volume fell slightly by 0.9%.
Adjusted Operating income increased 16.3% to $406 million, while margin improved from 14.8% to 15.3%.
Outlook: Quest Diagnostics reaffirms 2025 guidance for <a target="_blank" href="https://www.benzinga.com/news/earnings/25/01/43346695/quest-diagnostics-delivers-q4-earnings-beat-the-details" rel="noreferrer noopener">revenue of $10.70 billion—$10.85 billion</a> versus the consensus of $10.78 billion and adjusted EPS of $9.55-$9.80 compared to the consensus of $9.68.
In February, Quest agreed to acquire select assets of Fresenius Medical Care AG&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMS#NYSE">FMS</a>) wholly owned Spectra Laboratories. Financial terms were not disclosed. The acquisition is expected to close in the second half of 2025. The transition of services is expected to be <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43910114/fresenius-medical-care-announces-divestment-of-select-laboratory-assets-to-quest-diagnostics" rel="noreferrer noopener">complete by early 2026</a>.
In addition, under a separate agreement, Quest will provide comprehensive laboratory services related to end-stage kidney disease and specialized water testing for patients and providers served by dialysis centers operated by Fresenius Medical Care and its wholly owned and joint-venture partners in the U.S.
In February, GRAIL Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAL#NASDAQ">GRAL</a>) and Quest Diagnostics announced the initial phase of a program to improve provider access to GRAIL&#8217;s Galleri multi-cancer early detection test.
Providers can now order the Galleri test directly from GRAIL through the Quest Diagnostics connectivity system that enables providers in the U.S. to order and receive reports of laboratory tests electronically through Quest&#8217;s Quanum laboratory portal and more than 900 electronic health record (EHR) systems. More than 500,000 providers used the Quest connectivity <a href="https://www.benzinga.com/pressreleases/25/02/n43657458/grail-and-quest-diagnostics-provide-grails-galleri-multi-cancer-early-detection-mced-test-through-" target="_blank" rel="noreferrer noopener">system last year</a>.
William Blair writes, &#8220;At first glance, these results are in line with what we would expect from Quest — consistent and with little drama.&#8221;
&#8220;We remain comfortable with the 2025 guide, as Quest continues to benefit from prudent utilization assumptions, mix benefits, flattish unit pricing, a more favorable regulatory environment and plenty of acquisition targets,&#8221; analyst Andrew Brackmann noted.
The William Blair analyst added, &#8220;Beyond the favorable industry backdrop, we believe Quest should be well insulated from macroeconomic noise, with the overwhelming majority of revenue coming from the U.S. and what we think will be minimal (likely offset) impact from tariffs.&#8221; The analyst reiterated the Outperform rating.
DGX Price Action: Quest Diagnostics stock is up 7.83% to $174.53 at publication on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44921668/3m-stock-surges-after-q1-beat-as-2025-outlook-flags-tariff-pressure" target="_blank" rel="noreferrer noopener">3M Stock Surges After Q1 Beat As 2025 Outlook Flags Tariff Pressure</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Biotech

Large Cap

Guidance

Health Care

Reiteration

Movers

General

GRAL

Quest Diagnostics Revenue Rebound, Strategic Moves Fuel Outlook Confidence

U.S. stocks were higher, with the Dow Jones index gaining around 600 points on Tuesday.
Shares of Quest Diagnostics Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) rose sharply during Tuesday's session following <a href="https://www.benzinga.com/quote/DGX/earnings">better-than-expected first-quarter earnings.</a>
Quest Diagnostics reported quarterly earnings of $2.21 per share which beat the analyst consensus estimate of $2.15 per share. The company reported quarterly sales of $2.65 billion which beat the analyst consensus estimate of $2.63 billion.
Quest Diagnostics shares jumped 7.3% to $173.60 on Tuesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>PureCycle Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCT#NASDAQ">PCT</a>) gained 15% to $6.39. PureCycle announced the sale of approximately $30 million in revenue bonds.</li>
<li>Hesai Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSAI#NASDAQ">HSAI</a>) shares jumped 15% to $13.36. Hesai introduced Infinity Eye, which will be available in three tailored versions A, B, and C. Each one caters to different levels of autonomous driving from basic assisted features to full automation.</li>
<li>NovaGold Resources Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NG#NYSE">NG</a>) gained 14.7% to $3.5697 after the company and Paulson Advisers agreed to acquire Barrick&#8217;s 50% stake in Donlin Gold, forming a new partnership to develop the project.</li>
<li>Cipher Mining Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIFR#NASDAQ">CIFR</a>) surged 14.5% to $2.68.</li>
<li>First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) gained 13.7% to $139.15 after the US finalized plans to impose tariffs on most solar cells imported from Southeast Asia.</li>
<li>SolarEdge Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) jumped 13.6% to $13.74. SolarEdge Technologies will report financial results for the first quarter, before market open on Tuesday, May 6.</li>
<li>Webull Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BULL#NASDAQ">BULL</a>) shares rose 13.5% to $27.97.</li>
<li>Calix, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CALX#NYSE">CALX</a>) jumped 13.1% to $37.59 after the company reported better-than-expected first-quarter financial results and issued second-quarter guidance above estimates. Additionally, the company announced an authorized increase to its stock repurchase program.</li>
<li>Bitdeer Technologies Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) jumped 12.2% to $8.52.</li>
<li>Riot Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) gained 11.1% to $6.99.</li>
<li>Equifax Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>) gained 11% to $238.84 after the company reported better-than-expected first-quarter financial results. The company also authorized a $3 billion buyback and raised is dividend.</li>
<li>Seres Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) gained 10.5% to $8.27.</li>
<li>Akso Health Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHG#NASDAQ">AHG</a>) gained 8.8% to $1.22.</li>
<li>Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) rose 8.8% to $213.04.</li>
<li>Pentair plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNR#NYSE">PNR</a>) climbed 7.3% to $84.70 after the company reported first-quarter financial results and beat its adjusted EPS and revenue estimates.</li>
<li>3M Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>) shares gained 6.8% to $134.63 after the company reported better-than-expected first-quarter financial results.</li>
<li>Danaher Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) rose 5.8% to $195.64 after the company reported better-than-expected first-quarter EPS and revenue.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44922024/how-to-earn-500-a-month-from-philip-morris-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Philip Morris Stock Ahead Of Q1 Earnings</a> </li>
</ul>
Photo via Shutterstock

Intraday Update

BTDR

BULL

CALX

CIFR

CVNA

FSLR

HSAI

MCRB

RIOT

SEDG

Quest Diagnostics Posts Better-Than-Expected Earnings, Joins Pentair, 3M, Danaher And Other Big Stocks Moving Higher On Tuesday

WIIM

Quest Diagnostics shares are trading higher following a Q1 adjusted EPS and revenue beat.

Quest Diagnostics Reaffirms 2025 Guidance For Revenue Of $10.70B-$10.85B (Vs. Cons. Of $10.78B), Adjusted EPS Of $9.55-$9.80 (Vs. Cons. Of $9.68)

Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) reported quarterly earnings of $2.21 per share which beat the analyst consensus estimate of $2.15 by 2.79 percent. This is a 8.33 percent increase over earnings of $2.04 per share from the same period last year. The company reported quarterly sales of $2.65 billion which beat the analyst consensus estimate of $2.63 billion by 0.83 percent. This is a 12.09 percent increase over sales of $2.37 billion the same period last year.

Quest Diagnostics Q1 2025 Adj EPS $2.21 Beats $2.15 Estimate, Sales $2.65B Beat $2.63B Estimate

<h3>Companies Reporting Before The Bell</h3>
• Valmont Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMI#NYSE">VMI</a>) is estimated to report quarterly earnings at $4.36 per share on revenue of $976.14 million. 
• Herc Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRI#NYSE">HRI</a>) is expected to report quarterly earnings at $2.21 per share on revenue of $847.18 million. 
• Peoples Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEBO#NASDAQ">PEBO</a>) is expected to report quarterly earnings at $0.73 per share on revenue of $113.55 million. 
• Mercantile Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBWM#NASDAQ">MBWM</a>) is likely to report quarterly earnings at $1.19 per share on revenue of $57.70 million. 
• Lockheed Martin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) is expected to report quarterly earnings at $6.34 per share on revenue of $17.79 billion. 
• Northern Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRS#NASDAQ">NTRS</a>) is likely to report quarterly earnings at $1.85 per share on revenue of $1.95 billion. 
• RTX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) is projected to report quarterly earnings at $1.35 per share on revenue of $19.79 billion. 
• Verizon Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>) is estimated to report quarterly earnings at $1.15 per share on revenue of $33.23 billion. 
• Moodys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCO#NYSE">MCO</a>) is estimated to report quarterly earnings at $3.54 per share on revenue of $1.88 billion. 
• Kimberly-Clark (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NYSE">KMB</a>) is estimated to report quarterly earnings at $1.89 per share on revenue of $4.88 billion. 
• Genuine Parts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPC#NYSE">GPC</a>) is estimated to report quarterly earnings at $1.68 per share on revenue of $5.83 billion. 
• Pentair (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNR#NYSE">PNR</a>) is estimated to report quarterly earnings at $1.01 per share on revenue of $988.89 million. 
• Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) is expected to report quarterly earnings at $2.15 per share on revenue of $2.63 billion. 
• Halliburton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) is estimated to report quarterly earnings at $0.60 per share on revenue of $5.28 billion. 
• MSCI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSCI#NYSE">MSCI</a>) is projected to report quarterly earnings at $3.91 per share on revenue of $744.21 million. 
• Northrop Grumman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>) is projected to report quarterly earnings at $6.26 per share on revenue of $9.93 billion. 
• 3M (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>) is expected to report quarterly earnings at $1.77 per share on revenue of $5.75 billion. 
• Equifax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>) is projected to report quarterly earnings at $1.40 per share on revenue of $1.42 billion. 
• PulteGroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHM#NYSE">PHM</a>) is expected to report quarterly earnings at $2.42 per share on revenue of $3.82 billion. 
• GE Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) is estimated to report quarterly earnings at $1.26 per share on revenue of $9.00 billion. 
• Elevance Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) is projected to report quarterly earnings at $11.38 per share on revenue of $46.29 billion. 
• Synchrony Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYF#NYSE">SYF</a>) is estimated to report quarterly earnings at $1.67 per share on revenue of $4.56 billion. 
• Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) is expected to report quarterly earnings at $1.64 per share on revenue of $5.58 billion. 
• Lotus Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOT#NASDAQ">LOT</a>) is estimated to report earnings for its fourth quarter. 
• United Community Banks (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UCB#NYSE">UCB</a>) is projected to report quarterly earnings at $0.56 per share on revenue of $247.09 million. 
• Invesco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVZ#NYSE">IVZ</a>) is likely to report quarterly earnings at $0.38 per share on revenue of $1.11 billion. 
• Iridium Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRDM#NASDAQ">IRDM</a>) is estimated to report quarterly earnings at $0.28 per share on revenue of $211.78 million. 
• Hope Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOPE#NASDAQ">HOPE</a>) is expected to report quarterly earnings at $0.19 per share on revenue of $114.97 million. 
• Dime Community Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCOM#NASDAQ">DCOM</a>) is expected to report quarterly earnings at $0.58 per share on revenue of $105.70 million. 
• Old National (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONB#NASDAQ">ONB</a>) is estimated to report quarterly earnings at $0.43 per share on revenue of $478.24 million. 
<h3>Companies Reporting After The Bell</h3>
• SAP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAP#NYSE">SAP</a>) is expected to report quarterly earnings at $1.42 per share on revenue of $9.07 billion. 
• Capital One Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>) is projected to report quarterly earnings at $3.75 per share on revenue of $10.06 billion. 
• Chubb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>) is estimated to report quarterly earnings at $3.22 per share on revenue of $11.22 billion. 
• Orrstown Financial Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORRF#NASDAQ">ORRF</a>) is estimated to report quarterly earnings at $0.93 per share on revenue of $54.62 million. 
• Pathward Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASH#NASDAQ">CASH</a>) is expected to report quarterly earnings at $2.78 per share on revenue of $259.27 million. 
• First Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRBA#NASDAQ">FRBA</a>) is expected to report quarterly earnings at $0.39 per share on revenue of $32.78 million. 
• Renasant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNST#NYSE">RNST</a>) is expected to report quarterly earnings at $0.61 per share on revenue of $170.28 million. 
• Steel Dynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STLD#NASDAQ">STLD</a>) is estimated to report quarterly earnings at $1.85 per share on revenue of $4.24 billion. 
• Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) is estimated to report quarterly earnings at $1.73 per share on revenue of $2.19 billion. 
• EQT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) is likely to report quarterly earnings at $0.91 per share on revenue of $2.00 billion. 
• Packaging Corp of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKG#NYSE">PKG</a>) is estimated to report quarterly earnings at $2.22 per share on revenue of $2.12 billion. 
• PennyMac Financial Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFSI#NYSE">PFSI</a>) is expected to report quarterly earnings at $2.82 per share on revenue of $517.92 million. 
• PennyMac Mortgage IT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PMT#NYSE">PMT</a>) is expected to report quarterly earnings at $0.39 per share on revenue of $92.33 million. 
• QCR Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCRH#NASDAQ">QCRH</a>) is expected to report quarterly earnings at $1.51 per share on revenue of $94.26 million. 
• Hanmi Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAFC#NASDAQ">HAFC</a>) is expected to report quarterly earnings at $0.57 per share on revenue of $63.43 million. 
• Monarch Casino &amp; Resort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRI#NASDAQ">MCRI</a>) is likely to report quarterly earnings at $1.03 per share on revenue of $123.82 million. 
• Pegasystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGA#NASDAQ">PEGA</a>) is expected to report quarterly earnings at $0.50 per share on revenue of $357.20 million. 
• Baker Hughes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>) is likely to report quarterly earnings at $0.48 per share on revenue of $6.52 billion. 
• Zurn Elkay Water Solns (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZWS#NYSE">ZWS</a>) is estimated to report quarterly earnings at $0.29 per share on revenue of $383.55 million. 
• Usana Health Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USNA#NYSE">USNA</a>) is expected to report quarterly earnings at $0.74 per share on revenue of $243.08 million. 
• Veritex Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VBTX#NASDAQ">VBTX</a>) is expected to report quarterly earnings at $0.51 per share on revenue of $110.68 million. 
• Enphase Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) is expected to report quarterly earnings at $0.76 per share on revenue of $361.15 million. 
• First Busey (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BUSE#NASDAQ">BUSE</a>) is expected to report quarterly earnings at $0.50 per share on revenue of $117.56 million. 
• West Fraser Timber (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFG#NYSE">WFG</a>) is expected to report quarterly earnings at $0.56 per share on revenue of $1.53 billion. 
• Weatherford International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WFRD#NASDAQ">WFRD</a>) is likely to report quarterly earnings at $0.89 per share on revenue of $1.21 billion. 
• Range Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRC#NYSE">RRC</a>) is projected to report quarterly earnings at $0.89 per share on revenue of $803.02 million. 
• Agree Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADC#NYSE">ADC</a>) is expected to report quarterly earnings at $1.05 per share on revenue of $166.00 million. 
• National Bank Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NBHC#NYSE">NBHC</a>) is likely to report quarterly earnings at $0.75 per share on revenue of $107.47 million. 
• Brandywine Realty Tr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDN#NYSE">BDN</a>) is projected to report quarterly earnings at $0.16 per share on revenue of $119.45 million. 
• MIND Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIND#NASDAQ">MIND</a>) is expected to report quarterly earnings at $0.18 per share on revenue of $12.20 million. 
• Manhattan Associates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>) is estimated to report quarterly earnings at $1.13 per share on revenue of $273.47 million. 
• Trustmark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRMK#NASDAQ">TRMK</a>) is estimated to report quarterly earnings at $0.82 per share on revenue of $195.35 million. 
• Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) is estimated to report quarterly earnings at $0.46 per share on revenue of $22.46 billion. 
• East West Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWBC#NASDAQ">EWBC</a>) is expected to report quarterly earnings at $2.06 per share on revenue of $652.47 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BUSE

CASH

DCOM

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

ENPH

EWBC

FRBA

HAFC

HOPE

IRDM

ISRG

MANH

MBWM

MCRI

MIND

MSCI

NBHC

NTRS

ORRF

PEBO

PEGA

PFSI

QCRH

RNST

STLD

TRMK

TSLA

USNA

VBTX

WFRD

Earnings Scheduled For April 22, 2025

Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) is preparing to release its quarterly earnings on Tuesday, 2025-04-22. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Quest Diagnostics to report an earnings per share (EPS) of $2.16.
The market awaits Quest Diagnostics's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Past Earnings Performance</h3>
During the last quarter, the company reported an EPS beat by $0.05, leading to a 6.83% drop in the share price on the subsequent day.
Here's a look at Quest Diagnostics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>2.18</td>
<td>2.26</td>
<td>2.34</td>
<td>1.85</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.23</td>
<td>2.30</td>
<td>2.35</td>
<td>2.04</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-7.000000000000001%</td>
<td>1.0%</td>
<td>-2.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745251254_0.png" alt="eps graph" />
<h3>Quest Diagnostics Share Price Analysis</h3>
Shares of Quest Diagnostics were trading at $163.8 as of April 18. Over the last 52-week period, shares are up 11567.39%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analysts' Take on Quest Diagnostics</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Quest Diagnostics.
Analysts have given Quest Diagnostics a total of 10 ratings, with the consensus rating being Neutral. The average one-year price target is $182.5, indicating a potential 11.42% upside.
<h3>Peer Ratings Overview</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of Labcorp Hldgs, DaVita and Chemed, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Labcorp Hldgs, with an average 1-year price target of $273.0, suggesting a potential 66.67% upside.</li>
<li>Analysts currently favor an Neutral trajectory for DaVita, with an average 1-year price target of $169.0, suggesting a potential 3.17% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Chemed, with an average 1-year price target of $667.0, suggesting a potential 307.2% upside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
Within the peer analysis summary, vital metrics for Labcorp Hldgs, DaVita and Chemed are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quest Diagnostics</td>
<td>Neutral</td>
<td>14.55%</td>
<td>$858M</td>
<td>3.24%</td>
</tr>
<tr>
<td>Labcorp Hldgs</td>
<td>Buy</td>
<td>9.76%</td>
<td>$896.30M</td>
<td>1.77%</td>
</tr>
<tr>
<td>DaVita</td>
<td>Neutral</td>
<td>4.73%</td>
<td>$1.07B</td>
<td>102.13%</td>
</tr>
<tr>
<td>Chemed</td>
<td>Outperform</td>
<td>9.23%</td>
<td>$234.12M</td>
<td>7.67%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Quest Diagnostics ranks in the middle for Consensus rating. It is at the bottom for Revenue Growth and Gross Profit, but at the top for Return on Equity among its peers.
<h3>Get to Know Quest Diagnostics Better</h3>
Quest Diagnostics Inc is a leading independent provider of diagnostic testing, information, and services in the us. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
<h3>Understanding the Numbers: Quest Diagnostics's Finances</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Quest Diagnostics's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 14.55%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Quest Diagnostics's net margin is impressive, surpassing industry averages. With a net margin of 8.39%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Quest Diagnostics's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 3.24%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Quest Diagnostics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.36%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.05.
<a href="https://www.benzinga.com/quote/DGX/earnings">To track all earnings releases for Quest Diagnostics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Examining the Future: Quest Diagnostics's Earnings Outlook

Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) has outperformed the market over the past 5 years by 291.15% on an annualized basis producing an average annual return of 305.18%. Currently, Quest Diagnostics has a market capitalization of $18.18 billion. 
Buying $1000 In DGX: If an investor had bought $1000 of DGX stock 5 years ago, it would be worth $963,529.41 today based on a price of $163.80 for DGX at the time of writing.
<h3>Quest Diagnostics's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745019021_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Quest Diagnostics's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) short percent of float has risen 3.52% since its last report. The company recently reported that it has 2.86 million shares sold short, which is 2.94% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.58 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Quest Diagnostics Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744812024_0_1.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Quest Diagnostics has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Quest Diagnostics's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Quest Diagnostics's peer group average for short interest as a percentage of float is 9.65%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Quest Diagnostics's Recent Short Interest

Looking into the current session, Quest Diagnostics Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) shares are trading at $167.17, after a 0.49% decrease. Over the past month, the stock decreased by 3.06%, but over the past year, it actually increased by 13603.28%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1744743630_0.png" alt="Past Year Chart" />

<h3>Quest Diagnostics P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 128.64 in the Health Care Providers &amp; Services industry, Quest Diagnostics Inc. has a lower P/E ratio of 21.85. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1744743630_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Price Over Earnings Overview: Quest Diagnostics

Mizuho analyst Ann Hynes maintains Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) with a Outperform and raises the price target from $178 to $189.

Mizuho Maintains Outperform on Quest Diagnostics, Raises Price Target to $189

Quest Diagnostics Announced The Launch Of A New Laboratory Blood Test Designed To Help Physicians Confirm Amyloid Brain Pathology Due To Alzheimer's Disease In Patients With Mild Cognitive Impairment Or Dementia

Press Releases

GRAIL and Quest Diagnostics Provide GRAIL's Galleri® Multi-Cancer Early Detection (MCED) Test Through the Quest Diagnostics Test Ordering System

Quest Diagnostics to Host Investor Day on March 19, 2025

Small Cap

Opinion

Investors Eye Biotech Sector as Cancer Therapy Market Surges

Fresenius Medical Care Announces Divestment of Select Laboratory Assets to Quest Diagnostics

Quest Diagnostics to Collaborate with Google Cloud to Streamline Data and Personalize Customer Experiences Using Generative AI

Quest Diagnostics to Highlight Strategic Priorities to Drive Sustainable Growth and Deliver Long-term Shareholder Value at 2025 Investor Day

Quest Diagnostics to Release First Quarter 2025 Financial Results on April 22, 2025

Quest Diagnostics Introduces HPV Specimen Self-Collection for Cervical Cancer Screening

Quest Diagnostics Launches New AD-Detect™ Blood Test to Aid in Confirming Alzheimer's Disease

Quest Diagnostics Reports First Quarter 2025 Financial Results; Reaffirms Revenue and Adjusted Diluted EPS Guidance for Full Year 2025

ONCY

POAI

RENB

RHHBY

TSX:ONC

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

Amedisys

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna Group

CorVel

CVS Health

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Fresenius Medical Care

Guardant Health

Hims & Hers Health, Inc. Class A Common Stock

Hims & Hers Health

LifeStance Health Group, Inc. - Common Stock

LifeStance Health Gr

Labcorp Hldgs

Pediatrix Medical Group, Inc. Common Stock

Pediatrix Medical Group

NeoGenomics

Option Care Health

OPKO Health

Premier

Pennant Gr

Privia Health Gr

RadNet

GeneDx Holdings Corp. - Class A Common Stock

GeneDx Holdings

Piper Sandler

Truist Securities

Barclays

Evercore ISI Group

Baird

Screenshot 2025-04-15 at 7.03.21 PM

MYNZ

Mainz Biomed Narrows Its Losses, Grows Revenue For Full Year 2024

Screenshot 2024-12-19 at 7.13.05 PM

Quest Diagnostics (NYSE: DGX) And Mainz Biomed (NASDAQ: MYNZ) Team Up To Commercialize ColoAlert Early Cancer Detection Screening In The U.S.

Comments

Quest Diagnostics

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL